DrugPatentWatch Database Preview
TRIFERIC AVNU Drug Patent Profile
Email this page to a colleague
When do Triferic Avnu patents expire, and what generic alternatives are available?
Triferic Avnu is a drug marketed by Rockwell Medical Inc and is included in one NDA. There is one patent protecting this drug.
This drug has twelve patent family members in eleven countries.
The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. There are twenty drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ferric pyrophosphate citrate profile page.
DrugPatentWatch® Generic Entry Outlook for Triferic Avnu
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 17, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TRIFERIC AVNU
| International Patents: | 12 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 11 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TRIFERIC AVNU |
| What excipients (inactive ingredients) are in TRIFERIC AVNU? | TRIFERIC AVNU excipients list |
| DailyMed Link: | TRIFERIC AVNU at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for TRIFERIC AVNU
Generic Entry Date for TRIFERIC AVNU*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TRIFERIC AVNU
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rockwell Medical Technologies, Inc. | Phase 4 |
| Rockwell Medical Technologies, Inc. | Phase 3 |
| Rockwell Medical Technologies, Inc. | Phase 2 |
Pharmacology for TRIFERIC AVNU
| Drug Class | Parenteral Iron Replacement Phosphate Binder |
| Mechanism of Action | Phosphate Chelating Activity |
US Patents and Regulatory Information for TRIFERIC AVNU
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rockwell Medical Inc | TRIFERIC AVNU | ferric pyrophosphate citrate | SOLUTION;INTRAVENOUS | 212860-001 | Mar 27, 2020 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | Y | ⤷ Try it Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TRIFERIC AVNU
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 2016940 | ⤷ Try it Free |
| Canada | 2638081 | ⤷ Try it Free |
| European Patent Office | 2016940 | ⤷ Try it Free |
| Spain | 2383713 | ⤷ Try it Free |
| Slovenia | 2016940 | ⤷ Try it Free |
| Austria | 554754 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
